Clinical Guest Contributors

  1. How AI Is Rewriting The Future Of TMF And Clinical Quality 10/29/2025

    Discover how AI is transforming the TMF from a reactive repository into a proactive, intelligent co-pilot for clinical trials.

  2. Trends In Rare Disease Trials: Recommendations 10/24/2025

    In the third article of this series, analyst reveal their top 6 recommendations for designing selection criteria and selecting solution options to optimize rare disease research outcomes.

  3. The Hidden Power Of Specialized Community Research Sites In Accelerating Clinical Trials 10/24/2025

    Tyler Research Institute founder G. Aaron DuVall explores how community sites can offer access to diverse patient populations and build processes tailored for chronic disease care to accelerate timelines and improve outcomes. 

  4. Regulatory Pathways — With Real-Life Examples — For Successful CGT Clinical Trials 10/24/2025

    Discover the most effective regulatory pathways used to support CGT development, including two real-life examples.

  5. Continuous Evidence Generation — Including RWE — Remains Critical To Vaccine Development 10/23/2025

    President of Takeda's Global Vaccine Business Unit Derek Wallace discusses the importance of continuous, real-world data collection in the context of vaccine development in low- and middle-income countries.

  6. How Redefining The Diagnostic Odyssey Can Lead To Better Patient Outcomes 10/22/2025

    Patient advocate Wendy Cogan calls for improved diagnostic pathways as a means to better clinical trial recruitment and design while telling the journey of her late husband's journey to a corticobasal degeneration(CBD)-frontal behavioral-spatial syndrome (FBS) diagnosis.

  7. Careful Outsourcing Proves Key To Targeted Protein Degradation Drug Development 10/21/2025

    Discover how partnerships — especially with capable CROs — as well as resilient supply chains, digital enablement, regulatory foresight, and specialized talent impact the success of targeted protein degradation therapies.

  8. What Can We Expect From The FDA In 2026? 10/20/2025

    Expert panelists at the 2025 RAPS Convergence discussed what lies ahead for the FDA in 2026.

  9. We Need Communication Beyond The "Blah, Blah, Blah" 10/20/2025

    Miscommunication can derail clinical trials and lengthen study timelines. Discover how to improve communication among sponsors, CROs, and sites, and thus run more effective clinical trials.

  10. 100% U.S. Drug Tariffs: Implications For Pharma And Outsourcing 10/17/2025

    Research Manager Mathini Ilancheran explores the effects of U.S. drug tariffs on global supply chains, multinational pharma firms, and critical partners across drug development.